ProfileGDS5678 / 1419987_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 66% 73% 65% 65% 68% 65% 65% 63% 66% 67% 65% 67% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9845866
GSM967853U87-EV human glioblastoma xenograft - Control 23.962266
GSM967854U87-EV human glioblastoma xenograft - Control 34.6586173
GSM967855U87-EV human glioblastoma xenograft - Control 43.8757165
GSM967856U87-EV human glioblastoma xenograft - Control 53.8831965
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.153268
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9845965
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9225165
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7358263
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0101766
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0457567
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9101365
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0632167
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9712866